Phase 2b Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients (OTR)
Interventional
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention
To determine if DFMO at 500 mg daily will be well tolerated and not affect organ transplant viability
for 12 months
Howard H Bailey, MD
Principal Investigator
University of Wisconsin, Madison
United States: Food and Drug Administration
2001-414
NCT00204789
July 2003
December 2007
Name | Location |
---|